

Discovery of lead compounds targeting CR-E1 for the treatment of psoriasis via regulation of Th17

CUROGEN Technology Co., Ltd.

CUROGEN

IMMUNOLOGY	Hit
Product Type	Small molecule
Indication	1st indication : Psoriasis, Psoriasis [MeSH term] 2nd indication : ulcerative colitis, Colitis, Ulcerative [MeSH term]
Target	CR-E1
MoA(Mechanism of Action)	CR-E1 inhibitor treatment → CR-E1 inhibition → targeted therapy for psoriasis 1) Anti-proliferative effect on keratinocytes 2) Anti-inflammatory effect by inhibiting Th17 cell immune response
Competitiveness	First-in-Class, Novel therapeutic target for autoimmune disease
Development Stage	Hit
Route of Administration	Enteral-Oral, Skin topical